Valuation: Novacyt

Market Cap 34.91M 40.03M 32.96M 29.93M 56.08M 3.84B 56.32M 395M 152M 1.95B 150M 147M 6.28B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 36.87M 42.28M 34.81M 31.61M 59.22M 4.06B 59.47M 417M 161M 2.06B 159M 155M 6.64B EV / Sales 2026 *
1.21x
EV / Sales 2027 * 1.14x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 week-4.32%
Current month-2.79%
1 month-10.81%
3 months+22.21%
6 months+27.15%
Current year+22.36%
1 week 0.49
Extreme 0.486
0.51
1 month 0.48
Extreme 0.485
0.55
3 years 0.3
Extreme 0.299
1.53
5 years 0.3
Extreme 0.299
5.83
Manager TitleAgeSince
Chief Executive Officer 53 01/05/2024
Director of Finance/CFO 44 01/01/2020
Chief Operating Officer - 01/11/2021
Director TitleAgeSince
Director/Board Member 75 03/07/2006
Director/Board Member 60 27/06/2017
Director/Board Member 44 02/01/2024
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-4.32%+6.45%-37.64% 40.03M
-7.15%+4.14% - - 1.27B
+1.71%+4.38%-32.05%-39.24% 695M
+2.70%-8.95%+60.11% - 356M
+4.06%+3.19%-42.55%-32.67% 122M
+1.53%+15.03%-10.36%+24.38% 76.54M
Average +0.57%+2.34%-3.68%-21.29% 503.44M
Weighted average by Cap. -2.50%-2.30%-5.11%-33.10%

Financials

2026 *2027 *
Net sales 30.52M 35.01M 28.82M 26.17M 49.04M 3.36B 49.24M 345M 133M 1.71B 131M 129M 5.49B 34.86M 39.98M 32.92M 29.89M 56M 3.84B 56.24M 394M 152M 1.95B 150M 147M 6.28B
Net income - -
Net Debt 1.96M 2.24M 1.85M 1.68M 3.14M 215M 3.16M 22.12M 8.54M 109M 8.43M 8.24M 352M 4.84M 5.55M 4.57M 4.15M 7.78M 533M 7.81M 54.77M 21.13M 271M 20.86M 20.4M 872M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
-
Date Price Change
18/09/26 €0.4870 +0.21%
17/09/26 €0.4860 -0.92%
16/09/26 €0.4905 -1.41%
15/09/26 €0.4975 -2.26%
14/09/26 €0.5090 0.00%

Annual profits - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!